Intelligence Feed event · Equity · 2026-06-29

    Zymeworks to Acquire Theravance Biopharma for $929 Million

    Question

    Zymeworks to Acquire Theravance Biopharma for $929 Million

    Direct answer

    Zymeworks (ZYME) is expanding its portfolio into respiratory care with the acquisition of Theravance Biopharma (TBPH). The deal is notable for its financing structure, utilizing a $350 million note from OMERS, which preserves Zymeworks' cash for its oncology pipeline. The acquisition provides Zymeworks with an immediate revenue stream from YUPELRI, a nebulized LAMA for COPD, marking a transition for the company toward a commercial-stage entity.

    Original publisher
    Market Ontology
    Evidence through
    2026-06-29
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Zymeworks to Acquire Theravance Biopharma for $929 Million”, revision 1, evidence through 2026-06-29. https://marketontology.com/market-events/2026-06-29/zymeworks-to-acquire-theravance-biopharma-for-929-million-05da74

    EQUITY
    Zymeworks to Acquire Theravance Biopharma for $929 Million
    Zymeworks (ZYME) is expanding its portfolio into respiratory care with the acquisition of Theravance Biopharma (TBPH). The deal is notable for its financing structure, utilizing a $350 million note from OMERS, which preserves Zymeworks' cash for its oncology pipeline. The acquisition provides Zymeworks with an immediate revenue stream from YUPELRI, a nebulized LAMA for COPD, marking a transition for the company toward a commercial-stage entity.
    TBPHZYME
    Impact
    65
    JUN 29
    SIG
    90%
    TBPHZYME
    Zymeworks to Acquire Theravance Biopharma for $929 Million
    Zymeworks (ZYME) is expanding its portfolio into respiratory care with the acquisition of Theravance Biopharma (TBPH). The deal is notable for its financing structure, utilizing a $350 million note from OMERS, which preserves Zymeworks' cash for its oncology pipeline. The acquisition provides Zymeworks with an immediate revenue stream from YUPELRI, a nebulized LAMA for COPD, marking a transition for the company toward a commercial-stage entity.
    → Consolidation in the biotech sector via cash-and-debt-funded acquisitions to acquire commercial-stage assets.
    Impact
    Zymeworks (ZYME) is expanding its portfolio into respiratory care with the acquisition of Theravance Biopharma (TBPH). The deal is notable for its financing structure, utilizing a $350 million note from OMERS, which preserves Zymeworks' cash for its oncology pipeline. The acquisition provides Zymeworks with an immediate revenue stream from YUPELRI, a nebulized LAMA for COPD, marking a transition for the company toward a commercial-stage entity.
    Affected
    TBPHZYME
    Transmission
    Consolidation in the biotech sector via cash-and-debt-funded acquisitions to acquire commercial-stage assets.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month